Physician profile
Amy Dial
NPI 1881435816
$3,596.60
in general payments reported to CMS, 2019-2025
19 companies · $2,684 in 2025
The $2,684 reported for 2025 was more than what 96% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $913 · 2025: $2,684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,364 · Education: $233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,364.06 |
| Education | $232.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $985.31 | 2024-2025 | |
| Janssen Biotech, INC. | $872.01 | 2024-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $248.50 | 2024-2025 | Entyvio |
| Gilead Sciences, INC. | $247.27 | 2025 | Livdelzi |
| Ipsen Biopharmaceuticals, INC | $199.11 | 2025 | Iqirvo |
| Exact Sciences Corporation | $152.49 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Phathom Pharmaceuticals, INC. | $143.94 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $128.79 | 2024-2025 | Xifaxan |
| Ardelyx, INC. | $125.01 | 2024-2025 | Ibsrela |
| Pfizer INC. | $115.09 | 2024-2025 | |
| Celltrion USA INC. | $104.02 | 2024-2025 | Zymfentra, Vegzelma |
| Regeneron Healthcare Solutions, INC. | $57.21 | 2025 | Dupixent |
| Boston Scientific Corporation | $47.53 | 2025 | Watchman Access System |
| Intercept Pharmaceuticals, INC. | $42.08 | 2025 | |
| Madrigal Pharmaceuticals | $30.25 | 2025 | Rezdiffra |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $28.88 | 2024 | |
| Pharmacosmos Therapeutics INC. | $28.49 | 2025 | Monoferric |
| Qol Medical, LLC | $23.01 | 2025 | Sucraid |
| Braintree Laboratories, INC. | $17.61 | 2025 | Sutab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Dial listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.